Advanced search
Publication Cover
Aging Health Volume 4, 2008 - Issue 3
Journal homepage
503
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Osteonecrosis of the Jaw – Relationship to Bisphosphonate Use: Commentary and Perspective

Aliya KhanMcMaster University, Divisions Endocrinology & Geriatrics, 209–331 Sheddon Avenue, Oakville, ONL6J 1X8, USA. [email protected]View further author information
Pages 217-219 | Published online: 02 Jun 2008

Bibliography

  • Marx RE : Pamidronate (Aredia®) and zoledronate (Zometa®) induced avascular necrosis of the jaws: a growing epidemic.J. Oral Maxillofac. Surg.61, 1115–1117(2003).
  • Ruggiero SL , MehrotraB, RosenbergTJ, EngroffSL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.J. Oral Maxillofac. Surg.62, 527–534(2004).
  • Tarassoff P , CsermakK: Avascular necrosis of the jaws: risk factors in metastatic cancer patients.J. Oral Maxillofac. Surg.61, 1238–1239(2003).
  • Durie BG , KatzM, CrowleyJ: Osteonecrosis of the jaw and bisphosphonates.N. Engl. J. Med.353(1), 99–102(2005).
  • Bamias A , KastritisE, BamiaCet al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol.23(34), 8580–8587(2005).
  • Marx RE , SawatariY, FortinM, BroumandV: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.J. Oral Maxillofac. Surg.63(11), 1567–1575(2005).
  • Brown JP , Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ167(10 Suppl.), S1–S34 (2002).
  • Black DM , DelmasPD, EastellRet al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356(18), 1809–1822(2007).
  • Peters E , LovasGL, WysockiGP: Lingual mandibular sequestration and ulceration.Oral Surg. Oral Med. Oral Pathol.75, 739–743(1993).
  • Khosla S , BurrD, CauleyJet al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for Bone and Mineral Research. J. Bone Miner. Res.22(10), 1479–1491(2007).
  • Lam DK , SándorGK, HolmesHI, Evans AW, Clokie CM: A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J. Can. Dent. Assoc.73(5), 417–422(2007).
  • Santini D , VincenziB, DicuonzoGet al.: Zoledronic acid induces significant and long lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res.9, 2893–2897(2003).
  • Bamias A , DimopoulosMA: Thalidomide and immunomodulatory drugs in the treatment of cancer.Expert Opin. Investig. Drugs14, 45–55(2005).
  • Reid I : Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Bone41(3), 318–320(2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.